Cargando…

Evaluating the real-life effect of MP-AzeFlu on asthma outcomes in patients with allergic rhinitis and asthma in UK primary care

BACKGROUND: MP-AzeFlu (Dymista®; spray of azelastine/fluticasone propionate) is the most effective allergic rhinitis (AR) treatment available. Its effect on asthma outcomes in patients with AR and asthma is unknown. METHODS: This pre-post historical cohort study, using the Optimum Patient Care Resea...

Descripción completa

Detalles Bibliográficos
Autores principales:	De Jong, Hilda J.I., Voorham, Jaco, Scadding, Glenis K., Bachert, Claus, Canonica, Giorgio Walter, Smith, Peter, Wahn, Ulrich, Ryan, Dermot, Castillo, Jose A., Carter, Victoria A., Murray, Ruth B., Price, David B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	World Allergy Organization 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7753940/ https://www.ncbi.nlm.nih.gov/pubmed/33376573 http://dx.doi.org/10.1016/j.waojou.2020.100490

Ejemplares similares

Allergic rhinitis and asthma symptoms in a real-life study of MP-AzeFlu to treat multimorbid allergic rhinitis and asthma
por: Price, David, et al.
Publicado: (2020)

MP-AzeFlu Improves the Quality-of-Life of Patients with Allergic Rhinitis
por: van Weissenbruch, Ranny, et al.
Publicado: (2020)

MP‐AzeFlu is more effective than fluticasone propionate for the treatment of allergic rhinitis in children
por: Berger, W., et al.
Publicado: (2016)

Real‐life effectiveness of MP‐AzeFlu in Irish patients with persistent allergic rhinitis, assessed by visual analogue scale and endoscopy
por: Kaulsay, Ranbir, et al.
Publicado: (2018)

Real-Life Effectiveness of MP-AzeFlu (Dymista(®)) in Swedish Patients with Persistent Allergic Rhinitis, Assessed by the Visual Analogue Scale
por: Stjärne, Pär, et al.
Publicado: (2023)

A multicenter, prospective, noninterventional study in a Norwegian cohort of patients with moderate-to-severe allergic rhinitis treated with MP-AzeFlu
por: Dollner, Ralph, et al.
Publicado: (2017)

Effects of MP-AzeFlu enhanced by activation of bitter taste receptor TAS2R
por: Ekstedt, Sandra, et al.
Publicado: (2020)

Superior effect of MP-AzeFlu than azelastine or fluticasone propionate alone on reducing inflammatory markers
por: Roca-Ferrer, Jordi, et al.
Publicado: (2018)

Evaluation of in vitro Penetration of Fluticasone Propionate from MP-AzeFlu and Fluticasone Propionate Nasal Spray Through EpiAirway™606 Tissues Using Vertical Diffusion Cells
por: Berger, William E, et al.
Publicado: (2020)

A Clinical Study to Assess the Efficacy and Safety of MP-AzeFlu Nasal Spray in Comparison to Commercially Available Azelastine Hydrochloride and Fluticasone Propionate Nasal Sprays in Chinese Volunteers with Allergic Rhinitis
por: Zhou, Bing, et al.
Publicado: (2023)

Effect of MP‐AzeFlu compared to monotherapy on COX‐2, PGE(2), and EP2 gene expression in upper airway mucosa
por: Vicens‐Artes, Sonia, et al.
Publicado: (2022)

Short and long-term safety of MP29-02*: a new therapy for the treatment of allergic rhinitis
por: Price, David, et al.
Publicado: (2013)

MP29-02*’s advanced delivery system contributes to its efficacy in patients with moderate/severe seasonal allergic rhinitis
por: Scadding, Glenis, et al.
Publicado: (2015)

A new therapy (MP29-02*) effectively targets the entire seasonal allergic rhinitis symptom complex
por: Price, David, et al.
Publicado: (2013)

A new therapy (MP29-02*) effectively controls nasal symptoms of seasonal allergic rhinitis irrespective of severity
por: Scadding, Glenis, et al.
Publicado: (2013)

A new allergic rhinitis therapy (MP29-02*) provides nasal and ocular symptom relief days faster than current firstline monotherapies
por: Hellings, Peter, et al.
Publicado: (2015)

A new therapy (MP29-02*) provides effective relief from all individual nasal and ocular symptoms of seasonal allergic rhinitis
por: Hellings, Peter, et al.
Publicado: (2013)

A new efficacy parameter (complete/near complete symptom relief) in allergic rhinitis management: results with a new therapy MP29-02*
por: Bousquet, Jean, et al.
Publicado: (2013)

Superior effect of MP‐AzeFlu compared to monotherapy with fluticasone propionate or azelastine on GILZ, MKP‐1 and TTP anti‐inflammatory gene expression in healthy and inflamed upper airway mucosa
por: Vicens‐Artés, Sònia, et al.
Publicado: (2022)

Real‐world benefits of allergen immunotherapy for birch pollen‐associated allergic rhinitis and asthma
por: Wahn, Ulrich, et al.
Publicado: (2018)

A new therapy (MP29-02*) effectively treats patients with seasonal allergic rhinitis who suffer most from the bothersome nasal symptom of congestion
por: Bachert, Claus, et al.
Publicado: (2013)

The hidden burden of adult allergic rhinitis: UK healthcare resource utilisation survey
por: Price, David, et al.
Publicado: (2015)

A review of the clinical efficacy and safety of MP-AzeFlu, a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate, in clinical studies conducted during different allergy seasons in the US
por: Prenner, Bruce M
Publicado: (2016)

Optimal management of allergic rhinitis
por: Scadding, Glenis K
Publicado: (2015)

The Comparative Bioavailability of Fluticasone and Azelastine Delivered as a Single Fixed Dose Combination (MP-AzeFlu) in Comparison to Two Different Formulations of Azelastine and Fluticasone Propionate Following Intranasal Administration in Healthy Chinese Volunteers
por: Qi, Wenyuan, et al.
Publicado: (2023)

UK prescribing practices as proxy markers of unmet need in allergic rhinitis: a retrospective observational study
por: Price, David B, et al.
Publicado: (2016)

P07 - Treatment load in the therapy management of allergic rhinitis: a UK retrospective database study
por: Carter, Victoria, et al.
Publicado: (2014)

Seasonal distribution of inhaled allergens in allergic asthma patients with or without allergic rhinitis
por: Tian, Ruxian, et al.
Publicado: (2022)

Allergens, germs and asthma
por: Scadding, Glenis Kathleen
Publicado: (2015)

Seasonal allergic rhinitis: fluticasone propionate and fluticasone furoate therapy evaluated
por: Kariyawasam, Harsha H, et al.
Publicado: (2010)

A common language to assess allergic rhinitis control: results from a survey conducted during EAACI 2013 Congress
por: Hellings, Peter W., et al.
Publicado: (2015)

A new intranasal therapy (MP29-02*) is more effective than current firstline therapy regardless of season, symptom or severity.
por: Bachert, Claus, et al.
Publicado: (2015)

EUFOREA Comment on a Misleading Allergic Rhinitis Report [Letter]
por: Scadding, Glenis K, et al.
Publicado: (2023)

Rhinitis and Sinusitis
por: Scadding, Glenis K.
Publicado: (2008)

Allergic Rhinitis in Childhood and the New EUFOREA Algorithm
por: Scadding, Glenis Kathleen, et al.
Publicado: (2021)

Self-assessment of Allergic Rhinitis and Asthma (SACRA) Questionnaire-based Allergic Rhinitis Treatment Improves Asthma Control in Asthmatic Patients with Allergic Rhinitis
por: Yasuo, Masanori, et al.
Publicado: (2017)

Allergic rhinitis: evidence for impact on asthma
por: Thomas, Mike
Publicado: (2006)

Mechanisims of asthma and allergic disease – 1066. Ceruloplasmin oxidase activity in allergic asthma and allergic rhinitis
por: Yalcin, Arzu Didem, et al.
Publicado: (2013)

Is suicidal ideation associated with allergic asthma and allergic rhinitis?
por: Bedolla-Barajas, Martín, et al.
Publicado: (2018)

Investigation of Allergic Sensitizations in Children With Allergic Rhinitis and/or Asthma
por: Dai, Lingman, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_nac31ljttm4013lhith45ciit1